Artelo Biosciences, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with FY2022. Artelo is a clinical-stage biopharmaceutical company developing therapies targeting lipid-signaling pathways. It reported no product revenue and has no approved products.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.696 million | $4.324 million |
| General and administrative expense | $4.234 million | $5.963 million |
| Total operating expenses / operating loss | $9.930 million | $10.287 million |
| Net loss | $9.289 million | $10.083 million |
| Operating cash used | $8.207 million | $8.008 million |
| Cash and cash equivalents at year-end | $2.815 million | $6.888 million |
| Current assets / current liabilities | $10.980 million / $1.291 million | $18.322 million / $0.998 million |
Cash, cash equivalents and investments totaled $10.4 million at December 31, 2023. Working capital was $9.689 million, down from $17.324 million. Total liabilities were $1.291 million, principally accounts payable and accrued liabilities; the filing reports no debt balance. No operating margin is meaningful because the company has no revenue.
Net loss improved by $0.794 million year over year, despite higher R&D spending, primarily because G&A declined, including lower stock-based compensation. Other income included a $0.641 million gain from changes in fair value of trading marketable securities. The company recorded $1.206 million of UK R&D tax credits in 2023, as an offset to R&D expense.
Business and development progress
- ART27.13: Phase 1b/2a CAReS study for cancer-related anorexia. Phase 1b enrollment was completed in Q1 2023; Phase 2a began in April 2023, with approval to enroll 40 patients randomized 3:1 to drug or placebo. As of March 2024, nine sites were open and full enrollment was projected by year-end 2024.
- ART26.12: Preclinical FABP5 inhibitor program, prioritized for chemotherapy-induced peripheral neuropathy. Regulatory-enabling studies were underway; first-in-human studies were anticipated in the second half of 2024, subject to study-resource availability and regulatory review.
- ART12.11: Proprietary CBD cocrystal in preclinical development for anxiety-related and other potential indications.
Changes, outlook and material risks
- R&D expense rose $1.372 million, while G&A fell $1.729 million; total operating expenses decreased $0.357 million.
- Management expected existing cash resources to fund planned operations into the second half of 2025. The company expects continued substantial funding needs and states that further capital will be required to continue operations beyond that period. Additional financing is not assured.
- Potential funding sources include equity or debt offerings, strategic arrangements and licensing. The $20 million equity line had provided $0.567 million through year-end 2023; the company also had an effective $75 million shelf registration, subject to stated public-float limits. Equity financing may dilute shareholders.
- Management cited possible faster cash use from development delays, changes in spending, and global or supply-chain disruptions. UK R&D tax-credit eligibility and potentially lower relief may change for accounting periods beginning on or after April 1, 2024.
- Key risks include clinical and regulatory failure or delay, patient recruitment and third-party supplier/CRO dependence, limited capital and staffing, patent-license obligations, controlled-substance regulation, competition, and Nasdaq listing compliance.
- The auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness because the company qualified for an exemption.
Important facts for investors to verify
- Whether CAReS Phase 2a enrollment and timing remain on track, and what final study results show.
- Current cash and investment balances, cash burn, and whether management’s projected runway remains achievable.
- Actual access to the equity line or other financing, including proceeds, terms, and dilution.
- Progress and costs for ART26.12 regulatory-enabling work and whether first-in-human timing is still expected in 2024.
- The impact of UK R&D tax-credit changes, and any material changes to trial costs or funding assumptions.